Inibitore della monoamino ossidasi (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inibitore della monoamino ossidasi" in Italian language version.

refsWebsite

Global rank Italian rank

15doi.org

2^nd place

7^th place

11nih.gov

4^th place

9^th place

3cambridge.org

305^th place

508^th place

2web.archive.org

1^st place

2wiley.com

222^nd place

243^rd place

2jamanetwork.com

2,650^th place

2,089^th place

1sciencedirect.com

149^th place

298^th place

1nature.com

234^th place

226^th place

1oadoi.org

799^th place

22^nd place

1psychiatrist.com

low place

cambridge.org

(EN) M. Versiani, A. E. Nardi e F. D. Mundim, Pharmacotherapy of Social Phobia: A Controlled Study with Moclobemide and Phenelzine, in The British Journal of Psychiatry, vol. 161, n. 3, 1992-09, pp. 353–360, DOI:10.1192/bjp.161.3.353. URL consultato il 24 aprile 2023.
(EN) Jonathan Davidson, J. Ingram Walker e Clinton Kilts, A Pilot Study of Phenelzine in the Treatment of Post-traumatic Stress Disorder, in The British Journal of Psychiatry, vol. 150, n. 2, 1987-02, pp. 252–255, DOI:10.1192/bjp.150.2.252. URL consultato il 24 aprile 2023.
(EN) J. Vallejo, J. Olivares e T. Marcos, Clomipramine versus Phenelzine in Obsessive–Compulsive Disorder: A Controlled Clinical Trial, in The British Journal of Psychiatry, vol. 161, n. 5, 1992-11, pp. 665–670, DOI:10.1192/bjp.161.5.665. URL consultato il 24 aprile 2023.

doi.org

dx.doi.org

(EN) Geoffrey K. Isbister, L. P. Hackett e Andrew H. Dawson, Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity: Moclobemide poisoning, in British Journal of Clinical Pharmacology, vol. 56, n. 4, 2003-10, pp. 441–450, DOI:10.1046/j.1365-2125.2003.01895.x. URL consultato il 24 aprile 2023.
John P. M. Finberg e Jose M. Rabey, Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology, in Frontiers in Pharmacology, vol. 7, 18 ottobre 2016, DOI:10.3389/fphar.2016.00340. URL consultato il 15 agosto 2019.
(EN) M. Versiani, A. E. Nardi e F. D. Mundim, Pharmacotherapy of Social Phobia: A Controlled Study with Moclobemide and Phenelzine, in The British Journal of Psychiatry, vol. 161, n. 3, 1992-09, pp. 353–360, DOI:10.1192/bjp.161.3.353. URL consultato il 24 aprile 2023.
(EN) Robin B. Jarrett, Martin Schaffer e Donald McIntire, Treatment of Atypical Depression With Cognitive Therapy or Phenelzine: A Double-blind, Placebo-Controlled Trial, in Archives of General Psychiatry, vol. 56, n. 5, 1º maggio 1999, pp. 431, DOI:10.1001/archpsyc.56.5.431. URL consultato il 24 aprile 2023.
R. Rothschild, H. M. Quitkin e F. M. Quitkin, A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives, in The International Journal of Eating Disorders, vol. 15, n. 1, 1994-01, pp. 1–9, DOI:10.1002/1098-108x(199401)15:1<1::aid-eat2260150102>3.0.co;2-e. URL consultato il 24 aprile 2023.
(EN) Jonathan Davidson, J. Ingram Walker e Clinton Kilts, A Pilot Study of Phenelzine in the Treatment of Post-traumatic Stress Disorder, in The British Journal of Psychiatry, vol. 150, n. 2, 1987-02, pp. 252–255, DOI:10.1192/bjp.150.2.252. URL consultato il 24 aprile 2023.
P. H. Soloff, J. Cornelius e A. George, Efficacy of phenelzine and haloperidol in borderline personality disorder, in Archives of General Psychiatry, vol. 50, n. 5, 1993-05, pp. 377–385, DOI:10.1001/archpsyc.1993.01820170055007. URL consultato il 24 aprile 2023.
(EN) J. Vallejo, J. Olivares e T. Marcos, Clomipramine versus Phenelzine in Obsessive–Compulsive Disorder: A Controlled Clinical Trial, in The British Journal of Psychiatry, vol. 161, n. 5, 1992-11, pp. 665–670, DOI:10.1192/bjp.161.5.665. URL consultato il 24 aprile 2023.
(EN) M. R. Liebowitz, E. Hollander e F. Schneier, Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders, in Acta Psychiatrica Scandinavica, vol. 82, S360, 1990, pp. 29–34, DOI:10.1111/j.1600-0447.1990.tb05321.x. URL consultato il 15 agosto 2019.
Joanna S Fowler, Jean Logan e Albert J Azzaro, Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157, in Neuropsychopharmacology, vol. 35, n. 3, 2010-02, pp. 623–631, DOI:10.1038/npp.2009.167. URL consultato il 19 giugno 2017.
Dale E. Edmondson, Claudia Binda e Andrea Mattevi, STRUCTURAL INSIGHTS INTO THE MECHANISM OF AMINE OXIDATION BY MONOAMINE OXIDASES A AND B, in Archives of biochemistry and biophysics, vol. 464, n. 2, 15 agosto 2007, pp. 269–276, DOI:10.1016/j.abb.2007.05.006. URL consultato il 19 giugno 2017.
C. M. B. Pare, C. Hallstrom e N. Kline, WILL AMITRIPTYLINE PREVENT THE "CHEESE" REACTION OF MONOAMINE-OXIDASE INHIBITORS?, in The Lancet, vol. 320, n. 8291, 24 luglio 1982, pp. 183–186, DOI:10.1016/S0140-6736(82)91030-3. URL consultato il 3 agosto 2019.
(EN) Francisco Lotufo-Neto, Madhukar Trivedi e Michael E. Thase, Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression, in Neuropsychopharmacology, vol. 20, n. 3, 1999-03, pp. 226–247, DOI:10.1016/S0893-133X(98)00075-X. URL consultato il 24 aprile 2023.
Beverly J. McCabe-Sellers, Cathleen G. Staggs e Margaret L. Bogle, Tyramine in foods and monoamine oxidase inhibitor drugs: A crossroad where medicine, nutrition, pharmacy, and food industry converge, in Journal of Food Composition and Analysis, vol. 19, 1º agosto 2006, pp. S58–S65, DOI:10.1016/j.jfca.2005.12.008. URL consultato il 19 giugno 2017.
(EN) David A. Flockhart, Dietary Restrictions and Drug Interactions With Monoamine Oxidase Inhibitors: An Update, in The Journal of Clinical Psychiatry, vol. 73, suppl 1, 27 luglio 2012, pp. 4461, DOI:10.4088/JCP.11096su1c.03. URL consultato il 24 aprile 2023.

jamanetwork.com

jamanetwork.com, https://jamanetwork.com/journals/jamapsychiatry/fullarticle/205023 Titolo mancante per url url (aiuto). URL consultato il 24 aprile 2023.

archpsyc.jamanetwork.com

(EN) Robin B. Jarrett, Martin Schaffer e Donald McIntire, Treatment of Atypical Depression With Cognitive Therapy or Phenelzine: A Double-blind, Placebo-Controlled Trial, in Archives of General Psychiatry, vol. 56, n. 5, 1º maggio 1999, pp. 431, DOI:10.1001/archpsyc.56.5.431. URL consultato il 24 aprile 2023.

nature.com

(EN) Francisco Lotufo-Neto, Madhukar Trivedi e Michael E. Thase, Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression, in Neuropsychopharmacology, vol. 20, n. 3, 1999-03, pp. 226–247, DOI:10.1016/S0893-133X(98)00075-X. URL consultato il 24 aprile 2023.

nih.gov

ncbi.nlm.nih.gov

H. P. Volz, C. H. Gleiter e H. J. Möller, [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge], in Der Nervenarzt, vol. 67, n. 5, maggio 1996, pp. 339–347. URL consultato il 19 giugno 2017.
John P. M. Finberg e Jose M. Rabey, Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology, in Frontiers in Pharmacology, vol. 7, 18 ottobre 2016, DOI:10.3389/fphar.2016.00340. URL consultato il 15 agosto 2019.
Alan G. Mallinger, Ellen Frank e Michael E. Thase, Revisiting the Effectiveness of Standard Antidepressants in Bipolar Disorder: Are Monoamine Oxidase Inhibitors Superior?, in Psychopharmacology bulletin, vol. 42, n. 2, 2009, pp. 64–74. URL consultato il 15 agosto 2019.
J. H. Dowson, MAO inhibitors in mental disease: their current status, in Journal of Neural Transmission. Supplementum, vol. 23, 1987, pp. 121–138. URL consultato il 15 agosto 2019.
J. C. Shih e K. Chen, Regulation of MAO-A and MAO-B gene expression, in Current Medicinal Chemistry, vol. 11, n. 15, agosto 2004, pp. 1995–2005. URL consultato il 19 giugno 2017.
Joanna S Fowler, Jean Logan e Albert J Azzaro, Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157, in Neuropsychopharmacology, vol. 35, n. 3, 2010-02, pp. 623–631, DOI:10.1038/npp.2009.167. URL consultato il 19 giugno 2017.
Dale E. Edmondson, Claudia Binda e Andrea Mattevi, STRUCTURAL INSIGHTS INTO THE MECHANISM OF AMINE OXIDATION BY MONOAMINE OXIDASES A AND B, in Archives of biochemistry and biophysics, vol. 464, n. 2, 15 agosto 2007, pp. 269–276, DOI:10.1016/j.abb.2007.05.006. URL consultato il 19 giugno 2017.

pubmed.ncbi.nlm.nih.gov

J. Buigues e J. Vallejo, Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks, in The Journal of Clinical Psychiatry, vol. 48, n. 2, 1987-02, pp. 55–59. URL consultato il 24 aprile 2023.
R. Rothschild, H. M. Quitkin e F. M. Quitkin, A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives, in The International Journal of Eating Disorders, vol. 15, n. 1, 1994-01, pp. 1–9, DOI:10.1002/1098-108x(199401)15:1<1::aid-eat2260150102>3.0.co;2-e. URL consultato il 24 aprile 2023.
P. H. Soloff, J. Cornelius e A. George, Efficacy of phenelzine and haloperidol in borderline personality disorder, in Archives of General Psychiatry, vol. 50, n. 5, 1993-05, pp. 377–385, DOI:10.1001/archpsyc.1993.01820170055007. URL consultato il 24 aprile 2023.
G. Lavian, J. P. Finberg e M. B. Youdim, The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine, in Clinical Neuropharmacology, 16 Suppl 2, 1993, pp. S1–7. URL consultato il 24 aprile 2023.

oadoi.org

Beverly J. McCabe-Sellers, Cathleen G. Staggs e Margaret L. Bogle, Tyramine in foods and monoamine oxidase inhibitor drugs: A crossroad where medicine, nutrition, pharmacy, and food industry converge, in Journal of Food Composition and Analysis, vol. 19, 1º agosto 2006, pp. S58–S65, DOI:10.1016/j.jfca.2005.12.008. URL consultato il 19 giugno 2017.

psychiatrist.com

(EN) David A. Flockhart, Dietary Restrictions and Drug Interactions With Monoamine Oxidase Inhibitors: An Update, in The Journal of Clinical Psychiatry, vol. 73, suppl 1, 27 luglio 2012, pp. 4461, DOI:10.4088/JCP.11096su1c.03. URL consultato il 24 aprile 2023.

sciencedirect.com

C. M. B. Pare, C. Hallstrom e N. Kline, WILL AMITRIPTYLINE PREVENT THE "CHEESE" REACTION OF MONOAMINE-OXIDASE INHIBITORS?, in The Lancet, vol. 320, n. 8291, 24 luglio 1982, pp. 183–186, DOI:10.1016/S0140-6736(82)91030-3. URL consultato il 3 agosto 2019.

web.archive.org

Atypical Depression in the 21st Century: Diagnostic and Treatment Issues | Psychiatric Times, su web.archive.org, 2 dicembre 2013. URL consultato il 24 aprile 2023 (archiviato dall'url originale il 2 dicembre 2013).
(EN) Practical Guide For Prescribing MAOIs: Debunking Myths And Removing Barriers. URL consultato il 19 giugno 2017 (archiviato dall'url originale il 7 luglio 2017).

wiley.com

doi.wiley.com

(EN) Geoffrey K. Isbister, L. P. Hackett e Andrew H. Dawson, Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity: Moclobemide poisoning, in British Journal of Clinical Pharmacology, vol. 56, n. 4, 2003-10, pp. 441–450, DOI:10.1046/j.1365-2125.2003.01895.x. URL consultato il 24 aprile 2023.

onlinelibrary.wiley.com

(EN) M. R. Liebowitz, E. Hollander e F. Schneier, Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders, in Acta Psychiatrica Scandinavica, vol. 82, S360, 1990, pp. 29–34, DOI:10.1111/j.1600-0447.1990.tb05321.x. URL consultato il 15 agosto 2019.